Eisai Innovation, Inc. — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)
Co-investorsDroia VenturesNovartis Venture FundRA Capital
Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells.
AI & Machine LearningBiotechHealthtechSan Carlos, US
Yue Clare Lou(Co-Founder & CEO)inYue Lou(Executive Officer, Director)
BoardKevin Barrett(Director)Altar Munis(Director)
Co-investorsSBI HoldingsFifty YearsFREEFLOW
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.